The safety profile of @entity2892 /cilastatin: worldwide clinical experience based on 3470 XXXX .

@entity1 @entity1712 @entity410 @entity2892 @entity390 @entity1910 @entity294 @entity391 @entity9234 @entity3002 @entity8307 @entity111 @entity177 @entity110
The relative safety of @entity2892 / @entity9234 for 3470 @entity1 was reviewed to see if the safety profile was similar to that seen for the first 1723 @entity1 treated. The most common clinical adverse experiences were local ones related to the site of intravenous infusion. Gastrointestinal adverse experiences included @entity390 , @entity391 , or @entity294 . The frequency of @entity8307 was low (0 X 1%). The most common central @entity3002 was @entity410 . The most common background factor was central @entity3002 including prior history of @entity410 . Dermatological adverse experiences included @entity1910 , @entity111 and @entity110 . Bleeding and @entity177 were uncommon. The most common laboratory changes included transient increased liver function values, @entity1712 , positive Coombs' test (not associated with haemolysis) and increased platelets. The current clinical and laboratory safety data are similar to those obtained in the early part of the clinical trials.
